Ampicillin sulbactam: Difference between revisions
Gerald Chi (talk | contribs) m (Gerald Chi moved page Ampicillin/sulbactam to Ampicillin sulbactam) |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 1: | Line 1: | ||
{{ | __NOTOC__ | ||
{{Ampicillin sulbactam}} | |||
{{CMG}} | |||
}} | |||
{{ | |||
==Overview== | |||
Ampicillin/sulbactam, the combination of [[ampicillin]] with [[sulbactam]] (an irreversible [[beta-lactamase inhibitor|beta-lactamase inhibitor]]), has an antimicrobial spectrum similar to that of [[amoxicillin]]-[[clavulanic acid|clavulanate]] that includes [[methicillin]]-sensitive strains of [[Staphylococcus aureus]], [[Enterobacteriaceae]] (but not resistant strains of [[Escherichia coli]] or [[Pseudomonas aeruginosa]]), and [[anaerobe]]s. The agent has been used effectively to treat polymicrobial intra-abdominal and pelvic infections. It may also be used for soft tissue infections secondary to human or animal bites.<ref name="Lode-2008">{{Cite journal | last1 = Lode | first1 = HM. | title = Rational antibiotic therapy and the position of ampicillin/sulbactam. | journal = Int J Antimicrob Agents | volume = 32 | issue = 1 | pages = 10-28 | month = Jul | year = 2008 | doi = 10.1016/j.ijantimicag.2008.02.004 | PMID = 18539004 }}</ref> | |||
==Category== | |||
Aminopenicillin | |||
==US Brand Names== | |||
Unasyn<sup>®</sup> | |||
Ampicillin | ==FDA Package Insert== | ||
'''[[Ampicillin sulbactam description|Description]]''' | |||
'''| [[Ampicillin sulbactam clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Ampicillin sulbactam microbiology|Microbiology]]''' | |||
'''| [[Ampicillin sulbactam indications and usage|Indications and Usage]]''' | |||
'''| [[Ampicillin sulbactam contraindications|Contraindications]]''' | |||
'''| [[Ampicillin sulbactam warnings|Warnings]]''' | |||
'''| [[Ampicillin sulbactam precautions|Precautions]]''' | |||
'''| [[Ampicillin sulbactam adverse reactions|Adverse Reactions]]''' | |||
'''| [[Ampicillin sulbactam overdosage|Overdosage]]''' | |||
'''| [[Ampicillin sulbactam clinical studies|Clinical Studies]]''' | |||
'''| [[Ampicillin sulbactam dosage and administration|Dosage and Administration]]''' | |||
'''| [[Ampicillin sulbactam compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]''' | |||
'''| [[Ampicillin sulbactam directions for use|Directions For Use]]''' | |||
'''| [[Ampicillin sulbactam how supplied|How Supplied]]''' | |||
'''| [[Ampicillin sulbactam other size packages available|Other Size Packages Available]]''' | |||
==Mechanisms of Action== | |||
[[ | Ampicillin inhibits bacterial cell wall synthesis by binding to [[penicillin]]-binding proteins which in turn inhibits the transpeptidation (cross-linking) of [[peptidoglycan]]. Thus, cell wall assembly is interrupted and bacteria are lyzed by [[autolysins]] and murein [[hydrolase]]s. Sulbactam irreversibly inhibit [[plasmid]]-mediated [[beta-lactamases]]which are frequently accountable for [[drug resistance]]. In addition, sulbactam has modest activity ''in vitro'' against strains of [[Acinetobacter baumannii]].<ref name="Higgins-2004">{{Cite journal | last1 = Higgins | first1 = PG. | last2 = Wisplinghoff | first2 = H. | last3 = Stefanik | first3 = D. | last4 = Seifert | first4 = H. | title = In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. | journal = Antimicrob Agents Chemother | volume = 48 | issue = 5 | pages = 1586-92 | month = May | year = 2004 | doi = | PMID = 15105109}}</ref> The presence of sulbactam in the formulation extends the spectrum of ampicillin to include beta-lactamase producing strains. | ||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] |
Revision as of 17:04, 16 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ampicillin/sulbactam, the combination of ampicillin with sulbactam (an irreversible beta-lactamase inhibitor), has an antimicrobial spectrum similar to that of amoxicillin-clavulanate that includes methicillin-sensitive strains of Staphylococcus aureus, Enterobacteriaceae (but not resistant strains of Escherichia coli or Pseudomonas aeruginosa), and anaerobes. The agent has been used effectively to treat polymicrobial intra-abdominal and pelvic infections. It may also be used for soft tissue infections secondary to human or animal bites.[1]
Category
Aminopenicillin
US Brand Names
Unasyn®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available
Mechanisms of Action
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins which in turn inhibits the transpeptidation (cross-linking) of peptidoglycan. Thus, cell wall assembly is interrupted and bacteria are lyzed by autolysins and murein hydrolases. Sulbactam irreversibly inhibit plasmid-mediated beta-lactamaseswhich are frequently accountable for drug resistance. In addition, sulbactam has modest activity in vitro against strains of Acinetobacter baumannii.[2] The presence of sulbactam in the formulation extends the spectrum of ampicillin to include beta-lactamase producing strains.
References
- ↑ Lode, HM. (2008). "Rational antibiotic therapy and the position of ampicillin/sulbactam". Int J Antimicrob Agents. 32 (1): 10–28. doi:10.1016/j.ijantimicag.2008.02.004. PMID 18539004. Unknown parameter
|month=
ignored (help) - ↑ Higgins, PG.; Wisplinghoff, H.; Stefanik, D.; Seifert, H. (2004). "In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains". Antimicrob Agents Chemother. 48 (5): 1586–92. PMID 15105109. Unknown parameter
|month=
ignored (help)